Biotech AG announced that has been out-licensed for the South Korean market. Marinomed's exclusive license partner is stock-listed Hanmi Pharmaceutical Co., Ltd. headquartered in Seoul. Under the agreement, Hanmi is responsible for pursuing local approval for the Carragelose nasal spray and will market and distribute the product in South Korea.

Currently, Carragelose products are available over the counter (OTC) without prescription in more than 40 countries. Carragelose has been well established to prevent respiratory infections by various viruses, including certain influenza virus strains and endemic coronaviruses. Since the beginning of the COVID-19 pandemic, Carragelose has been shown to effectively inactivate both wildtype and common variants of the new coronavirus SARS-CoV-2. Clinical data from an independent study in Argentina had demonstrated an 80 % reduction in PCR-confirmed COVID-19 cases in hospital staff after Carragelose-treatment.